Adaptive Biotechnologies Corporation Stock
Equities
ADPT
US00650F1093
Biotechnology & Medical Research
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
2.6 USD | -0.38% | +8.33% | -46.94% |
Financials (USD)
Sales 2024 * | 176M | Sales 2025 * | 221M | Capitalization | 377M |
---|---|---|---|---|---|
Net income 2024 * | -193M | Net income 2025 * | -145M | EV / Sales 2024 * | 1.6 x |
Net cash position 2024 * | 96.2M | Net cash position 2025 * | 242M | EV / Sales 2025 * | 0.61 x |
P/E ratio 2024 * |
-1.98
x | P/E ratio 2025 * |
-2.43
x | Employees | 709 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 97.1% |
Latest transcript on Adaptive Biotechnologies Corporation
1 day | -0.38% | ||
1 week | +8.33% | ||
Current month | -19.00% | ||
1 month | -9.72% | ||
3 months | -34.18% | ||
6 months | -41.51% | ||
Current year | -46.94% |
Managers | Title | Age | Since |
---|---|---|---|
Harlan Robins
FOU | Founder | 51 | 09-09-07 |
Chad Robins
CEO | Chief Executive Officer | 49 | 09-09-07 |
Kyle Piskel
DFI | Director of Finance/CFO | 40 | 21-10-27 |
Members of the board | Title | Age | Since |
---|---|---|---|
Robert Hershberg
BRD | Director/Board Member | 61 | 13-01-31 |
Peter Neupert
BRD | Director/Board Member | 68 | 13-12-31 |
Michael Pellini
BRD | Director/Board Member | 58 | 18-02-12 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
2.68% | 1 M€ | 0.00% | - |
Date | Price | Change | Volume |
---|---|---|---|
24-04-26 | 2.6 | -0.38% | 1,074,607 |
24-04-25 | 2.61 | +0.38% | 1,839,185 |
24-04-24 | 2.6 | +0.78% | 2,020,667 |
24-04-23 | 2.58 | +2.79% | 1,518,083 |
24-04-22 | 2.51 | +4.58% | 2,160,324 |
Delayed Quote Nasdaq, April 26, 2024 at 04:00 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-46.94% | 377M | |
-20.45% | 10.82B | |
+43.17% | 3.25B | |
-35.86% | 2.11B | |
-17.21% | 2.08B | |
-29.81% | 1.48B | |
+17.56% | 1.02B | |
-4.37% | 733M | |
-37.00% | 391M | |
+13.32% | 332M |
- Stock Market
- Equities
- ADPT Stock